EHC Quote, Financials, Valuation and Earnings

Pediatrix Medical Group, Inc. has a net margin of 11.82% compared to Encompass Health Corp.'s net margin of 14.55%. Encompass Health Corp.'s return on equity of 24.34% beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

Encompass Health Corp. has a consensus price target of $140.33, signalling upside risk potential of 41.22%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could grow by 2.06%. Given that Encompass Health Corp. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe Encompass Health Corp. is more attractive than Pediatrix Medical Group, Inc..

Encompass Health Corp. has a beta of 0.756, which suggesting that the stock is 24.396% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.542%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.73%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health Corp. pays 14.35% of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are larger than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. Encompass Health Corp.'s net income of $174.7M is higher than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 18.78x while Pediatrix Medical Group, Inc.'s PE ratio is 11.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.75x versus 0.99x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of 11.82% compared to Encompass Health Corp.'s net margin of -22162.75%. Encompass Health Corp.'s return on equity of 24.34% beat Kindly MD, Inc.'s return on equity of -91.57%.

Encompass Health Corp. has a consensus price target of $140.33, signalling upside risk potential of 41.22%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 211.41%. Given that Kindly MD, Inc. has higher upside potential than Encompass Health Corp., analysts believe Kindly MD, Inc. is more attractive than Encompass Health Corp..

Encompass Health Corp. has a beta of 0.756, which suggesting that the stock is 24.396% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.73%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health Corp. pays 14.35% of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. Encompass Health Corp.'s net income of $174.7M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 18.78x while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.75x versus 11.25x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of 11.82% compared to Encompass Health Corp.'s net margin of -10.08%. Encompass Health Corp.'s return on equity of 24.34% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

Encompass Health Corp. has a consensus price target of $140.33, signalling upside risk potential of 41.22%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 81.06%. Given that The Oncology Institute, Inc. has higher upside potential than Encompass Health Corp., analysts believe The Oncology Institute, Inc. is more attractive than Encompass Health Corp..

Encompass Health Corp. has a beta of 0.756, which suggesting that the stock is 24.396% less volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.902%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.73%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health Corp. pays 14.35% of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. Encompass Health Corp.'s net income of $174.7M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 18.78x while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.75x versus 0.67x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Universal Health Services, Inc. has a net margin of 11.82% compared to Encompass Health Corp.'s net margin of 8.43%. Encompass Health Corp.'s return on equity of 24.34% beat Universal Health Services, Inc.'s return on equity of 20.13%.

Encompass Health Corp. has a consensus price target of $140.33, signalling upside risk potential of 41.22%. On the other hand Universal Health Services, Inc. has an analysts' consensus of $250.35 which suggests that it could grow by 21.7%. Given that Encompass Health Corp. has higher upside potential than Universal Health Services, Inc., analysts believe Encompass Health Corp. is more attractive than Universal Health Services, Inc..

Encompass Health Corp. has a beta of 0.756, which suggesting that the stock is 24.396% less volatile than S&P 500. In comparison Universal Health Services, Inc. has a beta of 1.282, suggesting its more volatile than the S&P 500 by 28.162%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.73%. Universal Health Services, Inc. offers a yield of 0.39% to investors and pays a quarterly dividend of $0.20 per share. Encompass Health Corp. pays 14.35% of its earnings as a dividend. Universal Health Services, Inc. pays out 4.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are smaller than Universal Health Services, Inc. quarterly revenues of $4.5B. Encompass Health Corp.'s net income of $174.7M is lower than Universal Health Services, Inc.'s net income of $379.1M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 18.78x while Universal Health Services, Inc.'s PE ratio is 9.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.75x versus 0.79x for Universal Health Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.